PLX
Protalix Biotherapeutics Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 83.5% | 88.3% | 87.4% | 86.8% | 86.7% | 71.6% | 82.0% | 83.7% | 80.4% | 82.8% | 81.8% | 81.0% | |
| 69.8% | 78.5% | 76.9% | 70.8% | 61.8% | 39.2% | 26.9% | 52.9% | 30.7% | 28.0% | 26.9% | 17.8% | |
| 69.8% | 78.5% | 76.9% | 70.8% | 61.8% | 39.2% | 56.7% | 52.9% | 39.8% | 52.8% | 47.4% | 36.8% | |
| 2.4% | 2.1% | 0.8% | 2.4% | 7.7% | 10.4% | 2.9% | 4.7% | 8.2% | 6.2% | 4.0% | 10.7% | |
| 8.5% | 5.9% | 6.4% | 10.8% | 14.0% | 18.0% | 19.3% | 24.4% | 30.1% | 22.6% | 28.9% | 31.2% | |
| 14.4% | 10.0% | 10.6% | 10.6% | 10.5% | 11.6% | 15.3% | 13.5% | 17.3% | 12.9% | 13.6% | 15.3% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 170.9% | 88.8% | 112.1% | 143.3% | 186.5% | 254.9% | 139.8% | 108.2% | 119.1% | 60.2% | 41.1% | 41.4% | |
| 33.4% | 11.6% | 80.5% | 31.5% | 41.5% | 88.5% | 127.3% | 45.0% | 58.1% | 53.9% | 34.9% | 32.2% | |
| 11.7% | 5.7% | 65.5% | 8.2% | 0.0% | 12.0% | 88.2% | 1.6% | 2.0% | 27.3% | 2.0% | 1.7% | |
| 5.0% | 3.7% | 4.9% | 10.4% | 8.5% | 14.3% | 10.6% | 9.5% | 10.5% | 5.1% | 6.2% | 6.4% | |
| 86.0% | 74.1% | 28.7% | 64.1% | 78.5% | 112.3% | 0.1% | 37.9% | 50.5% | – | – | – | |
| -70.9% | 11.2% | -12.1% | -43.3% | -86.5% | -154.9% | -39.8% | -8.2% | -19.1% | 39.8% | 58.9% | 58.6% | |
| -307.5% | -188.5% | -258.6% | -412.6% | -527.6% | -750.9% | -511.3% | -509.0% | -698.8% | -451.9% | -515.4% | -467.5% | |
| 11.8% | 9.8% | 12.3% | 18.2% | 24.1% | 32.7% | 42.9% | 59.9% | 86.9% | 97.6% | 110.4% | 95.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.